AN2 Therapeutics (ANTX) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Yarrow Bioscience (YARW) over the past year, gaining 262.8% versus a loss of 7.6%. Yarrow Bioscience is the larger company by market cap ($186.1 million vs $174.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | YARW |
|---|---|---|
| Share price | $4.62 | $20.00 |
| Market cap | $174.15M | $186.09M |
| 1-day change | -1.39% | +0.65% |
| YTD return | +310.53% | -31.48% |
| 1-year return | +262.79% | -7.58% |
| 5-year return | — | -98.19% |
| EPS (TTM) | $-1.05 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $46.95 |
| 52-week low | $1.00 | $16.05 |
| Distance from 52-week high | -35.81% | -57.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +95.02% | +185.00% |
| Average volume | 240.21K | 88.98K |
| Shares outstanding | 37.74M | 9.30M |
| Employees | 21 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed YARW by 270.4 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ANTX vs YARW FAQ
Which is bigger, AN2 Therapeutics or Yarrow Bioscience?
Yarrow Bioscience (YARW) is larger, with a market capitalization of $186.09M compared with $174.15M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ANTX or YARW?
ANTX returned +262.79% over the past 12 months, compared with -7.58% for YARW (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Yarrow Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.